Monthly Archives: July 2026

Scientific Storytelling in Oncology: Building High-Impact Advisory Boards for the MENA Region 

Cancer

What is an Advisory Board? 

An advisory board is a strategic, invitation-only meeting convened by pharmaceutical, biotechnology, and medical device companies to seek expert guidance from external key opinion leaders (KOLs), healthcare professionals (HCPs), and clinical researchers. Oncology advisory boards, in particular, play a major role in optimizing treatment strategies and addressing emerging clinical challenges in cancer care. 

Unlike promotional symposia or commercial sales meetings, advisory boards are strictly scientific and consultative. They are designed to foster a two-way dialogue between industry leaders and clinical experts.   

Core Objectives of an Advisory Board 

  • Gather strategic insights: Obtain real-world perspectives on clinical trial designs, evolving treatment paradigms, unmet medical needs, and patient journey bottlenecks. 
  • Validate clinical data: Test hypotheses, review emerging data (such as phase trial results or postmarketing studies), and gauge how new therapies fit into everyday clinical practice. 
  • Shape educational initiatives: Understand regional clinical preferences to guide the development of continuing medical education (CME) programs, consensus statements, and medical communications. 
  • Inform market access: Evaluate health economics, reimbursement challenges, and local regulatory hurdles (particularly in dynamic markets like the MENA region). 

Why Are Advisory Boards Essential? 

The increasing burden of chronic diseases, including cancer and rare diseases, together with advances in therapeutic strategies, emphasize the need for close collaboration between the pharmaceutical industry and HCPs to translate scientific innovation into improved patient outcomes. Advisory boards play a critical role in facilitating this collaboration by providing a forum for expert discussions on best practices, emerging evidence, clinical trial data, and real-world experience, supporting the successful introduction and optimal use of new oncology medicines. 

Oncology advisory boards differ significantly from advisory boards of other diseases due to the inherent complexity of cancer, the rapidly advancing diagnostic and treatment landscape, and the need to continuously evaluate the real-world efficacy and safety profiles of emerging therapies. In the MENA region, these advisory boards facilitate the addressing of local evidence gaps, the alignment of treatment strategies with the genetic and demographic characteristics of the population, and increased access to innovative therapies.

The New Frontier of Oncology in MENA 

The MENA region, led by the UAE and Saudi Arabia, has rapidly evolved into a global powerhouse for healthcare innovation and recurrent pharmaceutical business, with oncology and rare diseases taking center stage. However, traditional advisory boards in this region frequently fall into the trap of “logistics-first” planning, prioritizing venues and travel over deep scientific engagement. 

To break through this noise, medical affairs teams must introduce scientific storytelling as the critical bridge between raw clinical data and stakeholder engagement. By transforming complex data into a cohesive, objective-driven narrative, scientific storytelling helps navigate the unique cultural and regulatory landscapes of the UAE and Saudi Arabia, ultimately generating actionable decision-making intelligence. 

Strategy, Insight, and Impact 

1. How does scientific storytelling improve oncologist engagement in MENA?  

Traditional advisory boards often suffer from ill-defined objectives and poor KOL engagement due to cluttered data presentation and a lack of narrative coherence. This hinders the generation of actionable items or clear clinical conclusions. While virtual advisory boards mitigate scheduling and travel barriers, they often lack the depth of in-person interactions. 

Scientific storytelling overcomes these hurdles by shifting the discussion from a purely data-driven format to an objective-driven framework. By emphasizing the underlying clinical rationale rather than isolated data points, it enables HCPs to better understand complex challenges and formulate real-world solutions. In culturally and linguistically diverse regions such as MENA, this approach bridges evidence gaps and leverages varied KOL perspectives to drive strategic insight. 

2. What are the latest oncology stakeholder engagement trends in Saudi Arabia and UAE?  

Saudi Arabia and the UAE are spearheading rapid growth in the region’s drug development market, driven by the burden of lifestyle-related cancer and enhanced diagnostic capabilities. Growing investments in oncology research and expanding healthcare infrastructure have accelerated the adoption of innovative treatments, including targeted therapies and immunotherapies. Recent IQVIA data underscores this momentum: of 183 global cancer drug launches, 53% were approved in Germany, followed by 31% in both Saudi Arabia and the UAE, with the UAE achieving some of the fastest time-to-availability metrics. 

Beyond oncology, rare diseases represent another critical priority for the MENA region due to a high prevalence of inherited disorders linked to factors such as high consanguinity rates. In response, governments across the Middle East are prioritizing rare disease pathways through dedicated funding and streamlined regulatory frameworks. 

3. How can advisory boards provide actionable intelligence beyond meeting minutes?

Advisory boards can generate far greater value than a simple record of discussions when insights shared by KOLs are systematically analyzed and translated into strategic, evidence-based deliverables. Turacoz transforms advisory board discussions into high-value strategic deliverables: 

  • Scientific facilitation and documentation: Driving focused engagement with KOLs while meticulously capturing discussion points. 
  • Structured meeting reports: Systematically synthesizing raw notes into comprehensive overviews of objectives, evidence reviewed, expert consensus, and action items. 
  • Executive summaries: Condensing meeting context, key insights, risks, and recommended next steps for leadership. 
  • White paper development: Translating board outcomes into scientifically robust papers integrating published evidence and real-world data to support clinical policy. 
  • Newsletter development: Preparing concise, stakeholder-focused updates to communicate clinical trial findings and evolving consensus

Partnering for Strategic Excellence in MENA 

The rapid growth in the oncology and rare disease sector has created a sustained demand for evidence-based communication, scientific platforms, and stakeholder engagement solutions, all of which Turacoz has consistently delivered. Turacoz has successfully collaborated with several leading pharmaceutical companies across the MENA region to conduct advisory boards in oncology (non-small cell lung cancer) and rare diseases (sickle cell disease). The consistent quality of these deliverables reinforces confidence in Turacoz’s scientific integrity and long-term commitment to the region.  

At Turacoz, we understand that impactful KOL engagement depends on meticulous planning and seamless execution. Accordingly, we link discussion points to external evidence, translating complex conversations into clear, actionable narratives that directly support informed decision-making.  

Elevate your MENA oncology strategy. Partner with Turacoz to turn your next advisory board into a hub of actionable intelligence and drive sustainable product growth. 

Author:

Dr Sucharita Das 

Senior Medical Writer 

Medical Services, Turacoz Healthcare Solutions

About the author: 

Dr. Sucharita is a Senior Medical Writer at Turacoz Healthcare Solutions with more than two years of experience in developing advisory board deliverables, drafting consensus manuscripts, and creating web-based encyclopedia content. She has hands-on experience supporting projects across the European and Middle Eastern markets, contributing to the development of high-quality, evidence-based scientific communications customized to regional healthcare needs. 

The Asynchronous Evolution: Why Modern Advisory Boards Are Moving Beyond the Weekend Meeting

Uncategorized

For decades, advisory boards (ad boards) have been one of the most valuable ways for Medical Affairs teams to engage key opinion leaders (KOLs), validate scientific evidence, and gather expert insights that shape clinical strategy. However, as healthcare becomes increasingly global, digital, and data-driven, the traditional model is showing its limitations.

Flying KOLs to a central location for a weekend meeting demands nearly 48 hours of coordination and travel for what is often only eight to ten hours of structured exchange. Valuable reflections may surface after the meeting ends, follow-up discussions become fragmented across email threads, and manual summaries capture only a fraction of the knowledge shared. As Courtney et al. (2020) observed, substantial operational effort often accompanies relatively limited strategic output.

A clear evolution is underway. Leading pharmaceutical organizations are adopting asynchronous advisory boards and hybrid expert-engagement models that allow experts to contribute over an extended period, optimizing insight generation rather than logistics.

What Are Asynchronous Advisory Boards?

Asynchronous advisory boards are expert engagement models in which advisors contribute over several days or weeks rather than during a single scheduled meeting. Using moderated discussion forums, surveys, evidence reviews, and virtual collaboration platforms, KOLs participate at their convenience, while Medical Affairs teams capture in-depth scientific insights.

This approach complements, rather than replaces, traditional live meetings by extending the dialogue beyond a single event and enabling continuous engagement across geographies and time zones.

Benefits of Asynchronous Expert Engagement Over Synchronous Engagement

The shift toward asynchronous engagement is not about eliminating face-to-face interaction but ensuring that every interaction creates greater scientific value. Modern virtual HCP engagement combines live discussions with structured asynchronous activities, capturing expert insights before, during, and after the meeting.

Eliminating the 48-Hour Overhead

A traditional in-person advisory board can consume nearly two full days of an advisor’s schedule before meaningful discussion even begins. Travel, hotel stays, and logistics often outweigh the discussion itself. Virtual and asynchronous formats change this equation by allowing advisors to participate only for the time genuinely required to review evidence and contribute to the discussion.

This flexibility also influences who can participate. Recent survey data found that most healthcare professionals prefer advisory meetings with a virtual component, a preference observed among younger, digitally native clinicians, with physicians citing flexibility and reduced disruption to patient care as the primary reasons (Petrus & Lam, 2024).

Asynchronous engagement also makes it easier to include historically underrepresented voices, including frontline specialists, rural healthcare professionals, and patient advocates who offer valuable real-world insights but may be less able to commit to extensive travel. Removing geographical and scheduling barriers broadens access to a more representative range of clinical experience.

Documentation is another advantage. Asynchronous platforms automatically create structured, traceable records of expert responses, providing a valuable audit trail that supports transparency and compliance in regulated industries such as pharmaceuticals.

Key Takeaway: The greatest value of asynchronous advisory boards is not reduced travel. It lies in enabling Medical Affairs teams to engage the right experts, capture more thoughtful scientific input, and build a stronger foundation for strategic decision-making.

Cultivating Deep Thinking Across Time Zones

Traditional advisory boards ask experts to interpret evidence and develop recommendations within a single agenda, favouring immediate responses over reflective analysis. Asynchronous engagement creates space for deeper thinking. Advisors can review the evidence and contribute after careful consideration, often uncovering insights that a time-limited meeting might miss.

 As one panel of Medical Affairs leaders from Alcon, BioMarin, and BeOne Medicines observed, asynchronous technology helps overcome structural barriers by making it easier to distribute information and gather KOL insights (Within3, 2025).

How Do Asynchronous Advisory Boards Generate Better Strategic Insights?

Efficiency alone does not create better scientific decisions. The real value lies in transforming expert conversations into actionable intelligence that supports long-term Medical Affairs strategy. Traditionally, an advisory board’s output has been a meeting report that captures only a fraction of the knowledge exchanged. Today, teams need to understand not only what experts said but also why they said it, where consensus exists, and how those insights should shape evidence generation and publication planning.

By expanding engagement across multiple touchpoints, such as moderated forums, surveys, evidence reviews, and follow-up discussions, organizations can generate comprehensive qualitative data than any single meeting could provide. This approach can reveal evolving patterns of thought throughout the engagement process.

AI-Assisted Theme Extraction: From Meeting Minutes to Strategic Intelligence

As advisory board programs become more digital and global, the volume of qualitative data can grow substantially. Manually reviewing hundreds of expert comments is time-consuming and may produce inconsistent results. This is where AI-assisted theme extraction is reshaping Medical Affairs workflows.

Modern large language models (LLMs) can rapidly organize qualitative feedback, identify recurring themes, and group similar viewpoints across discussions, allowing Medical Affairs teams to focus on interpreting findings rather than manually categorizing comments. Large language model tools have been shown to identify thematic structure in qualitative healthcare interview data that is consistent with traditional manual analysis, while reducing the time and labor required (Ashton & Chatfield, 2026).

However, technology alone cannot replace scientific expertise.  Te value of AI is in insight analysis, dependent on a clear strategic framework and well-curated data. Simply summarizing a meeting transcript is not enough (Medical Affairs Professional Society, 2025)

At Turacoz, AI-assisted analysis accelerates insight generation without replacing scientific judgment. Our medical writers and scientific communication specialists validate AI-generated themes, interpret findings within the clinical context, and develop deliverables—including executive summaries, consensus reports, and publication-ready content—that translate expert discussions into measurable impact.

Key Insight: AI can identify patterns faster than humans, but only experienced scientific experts can determine which patterns matter.

Traditional Advisory Boards vs. Asynchronous Advisory Boards

This comparison reflects a broader shift: pharmaceutical organizations increasingly measure advisory board success not by whether a meeting took place but by the quality and usability of the insights generated.

Running Multi-Phase Advisory Boards Across Different Time Zones

Bringing together experts across North America, Europe, and Asia has traditionally required compromises that limit participation or discussion time. An asynchronous model helps remove these constraints. A modern hybrid engagement program follows four phases:

Phase 1: Strategic Planning—Define objectives, identify evidence gaps, recruit the right KOLs, and share prereading materials.

Phase 2: Asynchronous Scientific Engagement—Facilitate moderated forums, conduct targeted surveys and evidence reviews, and support peer-to-peer dialogue.

Phase 3: Live Advisory Board Meeting—Discuss emerging themes, explore divergent viewpoints, and build consensus.

Phase 4: Insight Synthesis and Reporting—Conduct AI-assisted thematic analysis, validate the findings through expert review, and develop strategic recommendations.

This phase- based approach transforms advisory boards into continuous engagement programs that generate value before, during, and after the live meeting.

From One-Off Meetings to Continuous Scientific Communities

The most significant evolution in advisory boards is not technological—it is philosophical. For decades, advisory boards were discrete events planned months in advance, with engagement typically resuming only in the next cycle. Forward-thinking Medical Affairs teams now recognize that the greatest value lies not in individual meetings but in continuous scientific engagement.

The Medical Affairs Professional Society has described this as an evolution from the pandemic-era meetings on Zoom to platforms where KOLs interact with content and each other over time rather than in a single decided meet (Medical Affairs Professional Society, 2023). The outcome is not just logistical relief, but an extended engagement across multiple touchpoints resulting in richer, more collegial relationships with advisors than an isolated, one-off session.

Key Takeaway: The future of advisory boards is not defined by where experts meet but by how effectively they collaborate over time.

The Turacoz Advantage: Technology-Enabled, Human-Led

Technology has transformed how pharmaceutical organizations collect, organize, and analyze scientific information, but it cannot replace scientific judgment. At Turacoz, we believe the future of advisory board engagement lies in combining technology-enabled insight generation with experienced medical communications professionals who understand the clinical and regulatory context behind every discussion.

Our Human-at-the-Helm philosophy ensures that AI accelerates analysis without replacing expert interpretation. We integrate medical writing, scientific and medical communications, Medical Affairs consulting, AI-assisted qualitative analysis, consensus development, and executive reporting to transform advisory board discussions into strategic assets that support publication planning, evidence generation, and informed decision-making.

Rather than simply facilitating meetings, we partner with Medical Affairs teams to design engagement models that generate measurable scientific value, moving beyond operational efficiency toward evidence-driven collaboration.

Author:

Shruti Kadam

Lead Medical Writer

Medical Services, Turacoz Healthcare Solutions

About the author:

Shruti is a Lead Medical Writer at Turacoz with nearly five years of experience developing scientific and medical communications, preceded by five years in R&D in Plant Sciences. Her work spans regulatory documents, clinical study reports, manuscripts, and medico-marketing materials across multiple therapeutic areas. Grounded in a life sciences background, she specializes in literature research, data interpretation, and evidence-based writing that meets industry quality standards.

References:

Ashton, T., & Chatfield, S. (2026). AI-enhanced qualitative analysis in healthcare: Unlocking insight from interviews of leadership at top-performing academic medical centres. Healthcare (Basel, Switzerland), 14(2), 248.

Courtney, W. T., Hartley, B. K., Rosswurm, M., LeBlanc, L. A., & Lund, C. J. (2020). Establishing and leveraging the expertise of advisory boards. Behaviour Analysis in Practice, 14(1), 253–263. https://doi.org/10.1007/s40617-020-00503-1

Medical Affairs Professional Society. (2023, November 14). Moving beyond ad boards: Asynchronous HCP engagement strategies. https://medicalaffairs.org/ad_boards-asynchronous-hcp-engagement/

Medical Affairs Professional Society. (2025, July 15). AI in medical insights: From implementation to impact in Medical Affairs. https://medicalaffairs.org/innovate-articles-ai-medical-affairs-insights-fawg-forum/

Petrus, C., & Lam, H. (2024). Considerations for planning effective and appealing advisory boards and other small-group meetings with health care providers: Importance of participant preferences. Pharmaceutical Medicine, 38(4), 311–320.

Within3. (2025, August 27). Engage. Analyze. Act: Mastering virtual advisory boards in pharma. https://within3.com/blog/engage-analyze-act-mastering-virtual-advisory-boards-in-pharma-2

Understanding Themes in Your Pharma Brand Story: A Messaging Strategy for Rapid HCP Engagement

Disease and Treatment, Medical Writing, Scientific Writing, Tips, , , ,

Why Short-Form Pharma Content is About Narrative, Not Format

High-impact communication is fundamentally about narrative. The right question is not which digital channel reaches a doctor fastest. It is what kind of content will make that HCP pause, read, and remember. 

That answer only comes from a well-constructed pharma brand narrative paired with clear, intentional content. 

A rapid-engagement asset needs as much planning and brainstorming as any longer-format deliverable. This is where most medical communications agencies lose the plot. They treat short-form as a lesser task, something to fill the gaps between bigger projects. In reality, concise HCP communications deserve their own creative brief and their own distinct strategic intent.

Aligning Your Pharma Messaging Strategy with Your Molecule’s Positioning

The starting point for an effective pharma content strategy is total clarity on how your molecule is positioned. Once that is established, your messaging themes follow naturally. 

  1. Prophylactic Agents (e.g., Vaccines, Chemo-Protective Agents) 

The messaging should resonate with themes of protection. Focus on: 

  • Broadening patient protection profiles. 
  • Reducing hospitalization rates. 
  • Saving productive workdays. 

Seasonal angles work particularly well here. A spring allergy season, for instance, is a ready-made context for a prophylactic molecule to offer timely, relevant value to an HCP. 

  1. Symptomatic Relief Molecules (e.g., Anti-Pyretics, Anti-Inflammatories, Analgesics) 

The narrative naturally shifts to themes of relief and everyday functional support. These messages resonate strongly with active, fitness-oriented individuals as well as elderly patient populations, making them highly versatile across diverse prescriber audiences. 

  1. Systemic Agents (e.g., Cardiovascular or Diabetes Medications) 

This tactical approach demands a deeper balance. Your messaging must navigate the pre-existing mental frameworks that specialists carry—specifically the trade-offs between efficacy and safety that are hardwired into clinical thinking. 

Effective healthcare professional marketing does not fight those frameworks; it latches onto them. The message should connect directly to those established clinical decision nodes and deliver its value from there. 

“A content-first, format-second strategy gives the target audience a sense of importance. It signals that short-form communications are handled with the same clinical rigor as a key opinion leader (KOL) deck, rather than being assembled as a lazy by-product of one.” 

The Real Cost of Treating Short-Form HCP Communications as an Afterthought

There is a pattern in pharma marketing that is easy to spot and hard to forgive: lifting text directly from a longer clinical paper, dropping it into an emailer, and adding extra visual noise to compensate for the lack of original thinking. HCPs recognize this immediately, and it actively erodes trust in the brand. 

Short-form assets deserve their own dedicated creative brief. When they are crafted with precision, they do something remarkable: they make the doctor feel genuinely considered, not just targeted. That feeling is the exact difference between a message that gets archived and one that builds true prescribing confidence. 

Building a Better Pharma Content Strategy for Modern HCPs

No single message will work uniformly across all prescriber audiences, molecules, and therapeutic areas. However, a targeted pharmaceutical positioning strategy built on authentic medical content consistently moves the needle. It improves prescription confidence and builds brand equity in therapeutic spaces where the science is strong, but the communication has historically been flat. 

The brands that make a real difference in their categories share one core discipline: they treat every communication touchpoint, however brief, with the same creative and strategic value they would give a major global launch. 

Ready to rethink your brand’s short-form communications?

At Turacoz Healthcare Solutions, we partner with pharmaceutical brands on a content-first strategy, whether you are launching a new molecule, entering a new market, or refreshing an established brand. Our short-form medical communications are built from the story outward, not the format inward.

Explore our services ↗

About the author

Ninad Nagarkar 

Strategic Solutions Specialist, Turacoz Healthcare Solutions 

Ninad works as a Strategic Solutions Specialist at Turacoz Healthcare Solutions, bringing over five years of experience in short-form communications, pharma brand narrative building, and strategic brand value creation. He has specialised in identifying the right format and channel for the right audience, with hands-on project experience spanning APAC, Europe, and the Middle East markets.